Literature DB >> 26887611

Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.

K Zhang1, H Yao2, Z Yang3, D Li4, L Yang3, Q Zou5, Y Yuan5, X Miao3.   

Abstract

INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor of the pancreas with poor prognosis. The lack of understanding of the molecular mechanisms of PDAC and biomarkers for early diagnosis might be two of the reasons for the poor prognosis of PDAC.
MATERIALS AND METHODS: ILK and ERP29 protein expressions in PDAC, peritumoral tissues, benign pancreatic lesions, and normal pancreatic tissues were measured by immunohistochemistry and the clinical and pathological significances of ILK and ERP29 in PDAC were analyzed.
RESULTS: The percentages of positive ILK and negative ERP29 expressions were significantly higher in PDAC tumors than in peritumoral tissues, benign pancreatic tissues, and normal pancreatic tissues (P < 0.01). Benign pancreatic lesions with positive ILK and negative ERP29 expressions exhibited dysplasia or intraepithelial neoplasia. The percentage of cases with positive ILK and negative ERP29 expressions was significantly lower in PDAC patients without lymph node metastasis and invasion, and having TNM stage I/II disease than in patients with lymph node metastasis, invasion, and TNM stage III/IV disease (P < 0.05 or P < 0.01). Kaplan-Meier survival analysis showed that positive ILK and negative ERP29 expressions were significantly associated with survival in PDAC patients (P < 0.001). Cox multivariate analysis revealed that positive ILK and negative ERP29 expressions were independent poor prognosis factors in PDAC patients.
CONCLUSIONS: Positive ILK and negative ERP29 expressions are associated with the progression of PDAC and poor prognosis in patients with PDAC.

Entities:  

Keywords:  Chronic pancreatitis; ERP29; ILK; Immunohistochemistry; Pancreatic ductal adenocarcinoma; Pancreatic intraepithelial neoplasia

Mesh:

Substances:

Year:  2016        PMID: 26887611     DOI: 10.1007/s12094-015-1331-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  28 in total

Review 1.  Adjuvant treatment of pancreatic cancer.

Authors:  John P Neoptolemos
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

Review 2.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

3.  ILK (beta1-integrin-linked protein kinase): a novel immunohistochemical marker for Ewing's sarcoma and primitive neuroectodermal tumour.

Authors:  D H Chung; J I Lee; M C Kook; J R Kim; S H Kim; E Y Choi; S H Park; H G Song
Journal:  Virchows Arch       Date:  1998-08       Impact factor: 4.064

4.  Inhibiting ERp29 expression enhances radiosensitivity in human nasopharyngeal carcinoma cell lines.

Authors:  Lin Qi; Ping Wu; Xin Zhang; Yuanzheng Qiu; Weihong Jiang; Donghai Huang; Yong Liu; Pingqing Tan; Yongquan Tian
Journal:  Med Oncol       Date:  2011-04-11       Impact factor: 3.064

5.  Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells.

Authors:  C Tan; P Costello; J Sanghera; D Dominguez; J Baulida; A G de Herreros; S Dedhar
Journal:  Oncogene       Date:  2001-01-04       Impact factor: 9.867

6.  Targeting ILK and β4 integrin abrogates the invasive potential of ovarian cancer.

Authors:  Yoon Pyo Choi; Baek Gil Kim; Ming-Qing Gao; Suki Kang; Nam Hoon Cho
Journal:  Biochem Biophys Res Commun       Date:  2012-09-28       Impact factor: 3.575

7.  ERp29 is a ubiquitous resident of the endoplasmic reticulum with a distinct role in secretory protein production.

Authors:  Steven D Shnyder; Michael J Hubbard
Journal:  J Histochem Cytochem       Date:  2002-04       Impact factor: 2.479

8.  The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth.

Authors:  Ronald P C Wong; Philip Ng; Shoukat Dedhar; Gang Li
Journal:  Mol Cancer Ther       Date:  2007-06       Impact factor: 6.261

Review 9.  Integrin-linked kinase 1: role in hormonal cancer progression.

Authors:  Valerie Cortez; Binoj C Nair; Dimple Chakravarty; Ratna K Vadlamudi
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

10.  Silencing of the integrin-linked kinase gene suppresses the proliferation, migration and invasion of pancreatic cancer cells (Panc-1).

Authors:  Xiang-Yu Zhu; Ning Liu; Wei Liu; Shao-Wei Song; Ke-Jian Guo
Journal:  Genet Mol Biol       Date:  2012-05-17       Impact factor: 1.771

View more
  2 in total

1.  Endoplasmic reticulum protein 29 (ERp29) as a novel prognostic marker and tumor suppressor in osteosarcoma.

Authors:  Parunya Chaiyawat; Dumnoensun Pruksakorn; Prach Pipatwattana; Areerak Phanphaisarn; Pimpisa Teeyakasem; Jeerawan Klangjorhor; Jongkolnee Settakorn
Journal:  J Bone Oncol       Date:  2019-03-19       Impact factor: 4.072

2.  Role of a genetic variation in the microRNA-4421 binding site of ERP29 regarding risk of oropharynx cancer and prognosis.

Authors:  Juliana Carron; Ana Paula Dalla Costa; José Augusto Rinck-Junior; Fernanda Viviane Mariano; Benilton de Sá Carvalho; Carmen Silvia Passos Lima; Gustavo Jacob Lourenço
Journal:  Sci Rep       Date:  2020-10-12       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.